Literature DB >> 17197131

Radiation dose and late failures in prostate cancer.

Peter B Morgan1, Alexandra L Hanlon, Eric M Horwitz, Mark K Buyyounouski, Robert G Uzzo, Alan Pollack.   

Abstract

PURPOSE: To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone.
METHODS: The data from 667 men with clinically localized intermediate- and high-risk prostate cancer treated with three-dimensional conformal RT alone were retrospectively analyzed. The interval hazard rates of DM and BF, using the American Society for Therapeutic Radiology and Oncology (ASTRO) and Phoenix (nadir + 2) definitions, were determined. The median follow-up was 77 months.
RESULTS: Multivariate analysis showed that increasing radiation dose was independently associated with decreased ASTRO BF (p < 0.0001), nadir + 2 BF (p = 0.001), and DM (p = 0.006). The preponderance (85%) of ASTRO BF occurred at < or =4 years after RT, and nadir + 2 BF was more evenly spread throughout Years 1-10, with 55% of BF in < or =4 years. Radiation dose escalation caused a shift in the BF from earlier to later years. The interval hazard function for DM appeared to be biphasic (early and late peaks) overall and for the <74-Gy group. In patients receiving > or =74 Gy, a reduction occurred in the risk of DM in the early and late waves, although the late wave appeared reduced to a greater degree.
CONCLUSION: The ASTRO definition of BF systematically underestimated late BF because of backdating. Radiation dose escalation diminished and delayed BF; the delay suggested that local persistence may still be present in some patients. For DM, a greater radiation dose reduced the early and late waves, suggesting that persistence of local disease contributed to both.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17197131      PMCID: PMC1892585          DOI: 10.1016/j.ijrobp.2006.10.023

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

1.  Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.

Authors:  P A Kupelian; D S Mohan; J Lyons; E A Klein; C A Reddy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-02-01       Impact factor: 7.038

2.  The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma.

Authors:  F A Vicini; L L Kestin; A A Martinez
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

3.  Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma.

Authors:  D A Kuban; A M el-Mahdi; P F Schellhammer
Journal:  Urology       Date:  1987-11       Impact factor: 2.649

4.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external beam radiation.

Authors:  A L Hanlon; G E Hanks
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

6.  Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients.

Authors:  J Crook; S Malone; G Perry; Y Bahadur; S Robertson; M Abdolell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-09-01       Impact factor: 7.038

7.  External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.

Authors:  A Pollack; L G Smith; A C von Eschenbach
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-09-01       Impact factor: 7.038

8.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Authors:  M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

9.  Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.

Authors:  E M Horwitz; A L Hanlon; W H Pinover; P R Anderson; G E Hanks
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

10.  A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy.

Authors:  Derek B Chism; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

View more
  14 in total

1.  A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: a radiobiological modeling study.

Authors:  M Fatyga; J F Williamson; N Dogan; D Todor; J V Siebers; R George; I Barani; M Hagan
Journal:  Med Phys       Date:  2009-09       Impact factor: 4.071

2.  B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer.

Authors:  Vinita Singh-Gupta; Sanjeev Banerjee; Christopher K Yunker; Joseph T Rakowski; Michael C Joiner; Andre A Konski; Fazlul H Sarkar; Gilda G Hillman
Journal:  Cancer Lett       Date:  2011-12-09       Impact factor: 8.679

3.  Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy.

Authors:  C Onal; S Sonmez; G Erbay; O C Guler; G Arslan
Journal:  Br J Radiol       Date:  2013-12-06       Impact factor: 3.039

4.  PKA knockdown enhances cell killing in response to radiation and androgen deprivation.

Authors:  Harvey H Hensley; Jean-Michel Hannoun-Levi; Paul Hachem; Zhaomei Mu; Radka Stoyanova; Li-Yan Khor; Sudhir Agrawal; Alan Pollack
Journal:  Int J Cancer       Date:  2010-10-19       Impact factor: 7.396

5.  Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy.

Authors:  Vinita Singh-Gupta; Hao Zhang; Christopher K Yunker; Zahra Ahmad; Danielle Zwier; Fazlul H Sarkar; Gilda G Hillman
Journal:  Pharm Res       Date:  2010-03-23       Impact factor: 4.200

Review 6.  [Radiotherapy for prostate cancer].

Authors:  Christian Stanek
Journal:  Wien Med Wochenschr       Date:  2007

Review 7.  Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?

Authors:  Romain Mathieu; Stephan M Korn; Karim Bensalah; Gero Kramer; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-08-08       Impact factor: 4.226

8.  What dose of external-beam radiation is high enough for prostate cancer?

Authors:  Thomas N Eade; Alexandra L Hanlon; Eric M Horwitz; Mark K Buyyounouski; Gerald E Hanks; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-29       Impact factor: 7.038

9.  Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells.

Authors:  Vinita Singh-Gupta; Hao Zhang; Sanjeev Banerjee; Dejuan Kong; Julian J Raffoul; Fazlul H Sarkar; Gilda G Hillman
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

10.  Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases.

Authors:  Chiara Lucrezia Deantoni; Andrei Fodor; Cesare Cozzarini; Claudio Fiorino; Chiara Brombin; Clelia Di Serio; Riccardo Calandrino; Nadia Di Muzio
Journal:  Br J Radiol       Date:  2020-01-31       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.